Biologics in the treatment of psoriasis: clinical and economic overview (Q37607414)

21 August 2017

0 references

1 reference

title

Biologics in the treatment of psoriasis: clinical and economic overview (English)

1 reference

21 August 2017

Yves Poulin

1

1 reference

21 August 2017

Richard G Langley

2

1 reference

21 August 2017

Henrique D Teixeira

3

1 reference

21 August 2017

Marie-Josée Martel

4

1 reference

21 August 2017

Sun Cheung

5

1 reference

21 August 2017

publication date

1 September 2009

1 reference

Journal of cutaneous medicine and surgery

21 August 2017

published in

1 reference

21 August 2017

volume

13 Suppl 2

1 reference

21 August 2017

page(s)

S49-57

1 reference

Psoriasis: epidemiology, clinical features, and quality of life

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2310%2F7750.2009.00021

Biologic therapeutics in the treatment of psoriasis. Part 1: review

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2009.00021

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2009.00021

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2009.00021

Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2009.00021

An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2009.00021

Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2009.00021

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2009.00021

Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2009.00021

CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2009.00021

Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2009.00021

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2009.00021

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2009.00021

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2009.00021

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2009.00021

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2009.00021

Sicily statement on evidence-based practice

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2009.00021

Evidence-based dermatology: number needed to treat and its relation to other risk measures

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2009.00021

Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2009.00021

Cardiovascular risk changes after lipid lowering medications: are they predictable?

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2009.00021

An evidence-based approach to studies of gastrointestinal therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2009.00021

Importance of benefit-to-risk assessment for disease-modifying drugs used to treat MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2009.00021

Algorithm for neuropathic pain treatment: an evidence based proposal.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2009.00021

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2009.00021

Different ways to describe the benefits of risk-reducing treatments: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2009.00021

An unadjusted NNT was a moderately good predictor of health benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2009.00021

The "number needed to treat" turns 20--and continues to be used and misused

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2009.00021

Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2009.00021

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2009.00021

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2009.00021

To test or not to test? An evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2009.00021

Economic evaluation of systemic therapies for moderate to severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2009.00021

New treatments for psoriasis: which biologic is best?

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2009.00021

Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2009.00021

Biologic Therapeutics in the Treatment of Psoriasis. Part 2: Practical Considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2009.00021

21 January 2018

Identifiers

DOI

10.2310/7750.2009.00021

1 reference

21 August 2017

1 reference